Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 18/20 | 0.51 |
| ▸ | MTOR | P42345 | 9/20 | 0.51 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.48 |
| ▸ | PI4KA | P42356 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16913898 | 0.85 | PIK3C3 (0.56) | PIK3C3PIK3CAPIK3CB | |
| SCHEMBL16913865 | 0.83 | PIK3C3 (0.58) | PIK3C3PIK3CAPIK3CD | |
| SCHEMBL29610307 | 0.80 | PIK3CA (0.59) | PIK3CAMTORPIK3R1PIK3CGPIK3CD | |
| SCHEMBL30333881 | 0.80 | PIK3CA (0.59) | PIK3CAMTORPIK3R1PIK3CGPIK3CD | |
| SCHEMBL462714 | 0.80 | PIK3CA (0.59) | PIK3CAMTORPIK3R1PIK3CGPIK3CD | |
| SCHEMBL789468 | 0.79 | PIK3C3 (0.52) | PIK3C3PIK3CAMTORPIK3R1PIK3CG | |
| SCHEMBL789760 | 0.79 | PIK3C3 (0.60) | PIK3C3PIK3CAMTORPIK3R1PIK3CG | |
| SCHEMBL16683557 | 0.79 | PIK3CA (0.63) | PIK3CAMTORPIK3R1PIK3CGPIK3CD | |
| SCHEMBL789774 | 0.77 | PIK3CA (0.56) | PIK3CAMTORPIK3R1PIK3CGPIK3CD | |
| SCHEMBL16990910 | 0.75 | PIK3C3 (1.00) | PIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3094325-B1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2021-10-13 | — | — | EP | disclosed |
| US-10538533-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2020-01-21 | — | — | US | disclosed |
| US-20180118762-A1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-03 | — | — | US | disclosed |
| US-20180118762-A1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-03 | — | — | US | disclosed |
| US-9802960-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802960-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9751854-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9751854-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170073326-A1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-16 | — | — | US | disclosed |
| US-20170073326-A1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-16 | — | — | US | disclosed |
| US-20150225422-A1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-13 | — | — | US | disclosed |
| US-20150225422-A1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-13 | — | — | US | disclosed |
| WO-2012037108-A1 | AMINOQUINOLINE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037108-A1 | AMINOQUINOLINE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118762-A1 | HETEROARYLS AND USES THEREOF | VPS35, VPS4B, VPS26B | PIK3C3 1186/4885PIK3CA 1261/4885MTOR 2025/4885 |
| US-10538533-B2 | Heteroaryls and uses thereof | VPS35, VPS4B, VPS26B | PIK3C3 1186/4885PIK3CA 1261/4885MTOR 2025/4885 |
| US-20150225422-A1 | HETEROARYLS AND USES THEREOF | VPS35, VPS4B, VPS26B | PIK3C3 1186/4885PIK3CA 1261/4885MTOR 2025/4885 |
| US-20170073326-A1 | HETEROARYLS AND USES THEREOF | VPS35, VPS4B, VPS26B | PIK3C3 1186/4885PIK3CA 1261/4885MTOR 2025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.